【摘要】 目的　研究高胆固醇血症 (HC)患者血小板CD62P及CD4 1表达及调脂药物干预后的变化。方法　 2 0例HC患者口服普伐他汀 10～ 2 0mg/d ,疗程 8周 ,治疗前后进行上述指标的检测。在体外研究中 ,于HC患者的血标本中加入不同浓度的普伐他汀 ,测定加药前后血小板CD62P及CD4 1表达的变化。结果　HC患者服用普伐他汀 4周和 8周后 ,CD62P平均荧光强度由治疗前的 31.8± 7.8分别降至2 7.2± 6 .9和 2 6 .8± 4.9;CD62P糖蛋白阳性血小板百分数由治疗前的 (31.3± 9.3) %分别降至 (2 6 .4±7 4) %和 (2 5 .3± 9.1) % ,P <0 .0 5。CD4 1由治疗前的 483.2± 2 6 3.9分别降至 348.1± 192 .4和 30 6 .8±12 8 0 ,P <0 .0 5。普伐他汀在体外对血小板CD62P及CD4 1的影响与与体内相似。血总胆固醇 (TC)和低密度脂蛋白 (LDL C)水平及血小板聚集功能在治疗后均明显下降 (P <0 .0 1)。结论　普伐他汀能改善HC患者血小板功能及CD62P和CD4 表达 ,可能是其促进动脉粥样斑块消退的机制之一 ;体外实验结果提示 ,调脂药物对血小板存在直接作用更多还原

【Abstract】 Objective To study in vitro and in vivo effect of hypercholesterolemia(HC) on expression of platelet CD 62P and CD 41 and their changes after treatment with pravastatin. Methods Twenty patients with HC were given 10～20?mg/d pravastatin orally for 4～8 weeks. Changes of blood cholesterol and expression of platelet CD 62P and CD 41 were detected by flow cytometry. Results After 4 and 8 weeks’ treatment, blood cholesterol level and platelet aggregation function decreased. The expression of CD 62P average fluorescence intensity decreased from 31.8±7.8 to 27.2±6.9 and 26.8±4.9;CD 62P (%) from (31.3±9.3)% to (26.4±7.4)% and (25.3±9 1)%(P<0.05);CD 41 from 483.2±263.9 to 348.1±192.4 and 306.8±128.0(P<0.05),respectively. Similar results were obtained in vitro study. Conclusion Improvement of platelet function and expressions of CD 62P and CD 41 in HC patients after prevastatin treatment may be resulted from enhancing arteriosclerosis regression. It suggested from the in vitro result that pravastatin might play a direct effect on platelet function.更多还原